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Abstract
The existence and identification of leukemia-initiating cells in adult acute B lymphoblastic leukemia (B-ALL) remain
controversial. We examined whether adult B-ALL is hierarchically organized into phenotypically distinct
subpopulations of leukemogenic and non-leukemogenic cells or whether most B-ALL cells retain leukemogenic
capacity, irrespective of their immunophenotype profiles. Our results suggest that adult B-ALL follows the
stochastic stem cell model and that the expression of CD34 and CD38 in B-ALL is reversibly and not
hierarchically organized.
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Currently, the long-term survival of adult B-ALL pa-
tients is less than 50 % [1–4]. To improve the cure
and survival rates of adults, there is an increasing need
to understand the biology of B-ALL and to
characterize the leukemia-initiating cells (LICs) in B-
ALL if they exist [5, 6]. Primary B-ALL cells from 25
adult patients (Additional file 1: Table S1) were intra-
venously transplanted into groups of adult NSI mice
[7–9] that had undergone preconditioning total body
irradiation. Twelve of the 25 samples engrafted suc-
cessfully (Additional file 2: Table S2). In the 12 cases
of successful engraftment, the mice died or developed
severe clinical signs suggestive of leukemia and requir-
ing euthanasia (Additional file 3: Table S3). Consistent
with primary xenografts, the human B-ALL cells that
expressed CD19, CD34, CD38, and CD45 in serial
transplanted NSI mice closely recapitulated the immu-
nophenotypes of the original patient (Additional file 4:
Figure S1, S2A). The morphology of leukemic cells in
the peripheral blood, spleens, and bone marrow (BM)
of xenografts resemble the original patient samples
(Additional file 5: Figure S2B). The CD34 and CD38
expression profiles of engrafted B-ALL cells from
transplanted NSI mice resemble the original patient
samples (Additional file 5: Figure S2A and Additional
file 6: Figure S3).
CD34 and CD38 molecules had been used as sur-
face markers to distinguish LICs [10, 11]. To identify
whether CD34 and CD38 can be used as LICs
markers in B-ALL cells, we purified CD34+CD38−,
CD34+CD38+, and CD34−CD38+ fractions from the
xenografts of patients #1 and #3. We subsequently
performed limited dilution transplantation of these
subpopulations in NSI mice. The purities of the sub-
populations were 97.3 % ± 0.89 (n = 12, Additional
file 7: Figure S4). The xenotransplantation results
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showed that each fraction of B-ALL cells from xenografts
of patients #1 and #3 was capable of engrafting in NSI
mice (Additional file 3: Table S3). Each subpopulation
from xenografts of patients individually reconstituted B-
ALL that contained CD34+CD38−, CD34+CD38+, and
CD34+CD38− fractions in NSI mice (Fig. 1). Genome-
wide expression profile analysis revealed that each
population was clustered closely in patients #1 and #3
(Additional file 8: Figure S5). RNA-Seq results were
further validated by measuring the messenger RNA
(mRNA) levels of oncogenesis-related genes using
quantitative RT-PCR (Additional file 9: Figure S6).
Next, we investigated whether expanded B-ALL cells
in vitro still maintain original expression profiles of
CD34 and CD38 and the LIC capacity. B-ALL cells from
11 of the 12 patient samples that successfully engrafted
in NSI mice attached to OP9 cells and proliferated
vigorously for at least 2 months (Additional file 10:
Table S4). We then monitored the expression profiles of
CD34 and CD38 in B-ALL cells in differential time. To
Fig. 1 Subpopulations of adult B-ALL cells reconstituted the leukemia in xenografts. Subpopulations of CD34+CD38−, CD34+CD38+, and CD34−CD38+
from xenografts of patients #1 and #3 were purified and injected into groups of NSI mice. a Representative FACS analysis of gated hCD45+ BM cells
from NSI recipients that were transferred with different subpopulations of engrafted B-ALL cells from patient #1. b Representative FACS analysis of
gated hCD45+ BM cells from NSI mice that were transferred with CD34+CD38+ and CD34−CD38+ fractions of engrafted B-ALL cells from patient #3
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our surprise, CD34+CD38− and CD34+CD38+ subpopu-
lations from patient #1 disappeared gradually in culture
(Fig. 2a). Six weeks after co-culture with OP9 cells, all
remaining leukemic cells were CD34−CD38+ (Additional
file 10: Table S4). To investigate whether CD34−CD38+
B-ALL cells after culture were still capable of engrafting
in mice, we further purified cultured CD34−CD38+ B-ALL
cells from patients #1, #4, and #7 and injected them into
groups of NSI mice. After 4 weeks transplantation, cul-
tured CD34−CD38+ B-ALL cells from patient reconsti-
tuted B-ALL consisting of CD34+CD38−, CD34+CD38+,
and CD34−CD38+subpopulations in mice (Fig. 2b and
Additional file 11: Table S5). Whole exome-sequencing
analysis [12] showed that B-ALL cells from co-culture
and B-ALL cells from xenografts shared similar SNP
profiles (Additional file 12: Figure S7). This result indi-
cates B-ALL cells maintain stable genetic characteris-
tics irrespective of phenotypes. Our results also showed
that individual B-ALL cells successfully engrafted in 4
of the 70 hosts and repopulated original surface profiles
(Additional file 13: Figure S8 and Additional file 14:
Table S6, detailed methodological information was in-
cluded in Additional file 17: supplementary methods.).
In conclusion, our results demonstrate that leukemic
blasts, irrespective of CD34 and CD38 expression, are
able to engraft immunodeficient mice and reconstitute
the original leukemia. Furthermore, we provide evidence
that the heterogeneity of CD34 and CD38 expression in
B-ALL obtained from patients reverses in different mi-
croenvironments. This phenotypic plasticity contrasts
the cancer stem cell model, which largely attributes het-
erogeneity to irreversible epigenetic changes.
Additional files
Additional file 1: Table S1. Characteristics of the 25 patients. (DOCX 17 kb)
Additional file 2: Table S2. Clinical information of the 25 B-ALL
patients. (DOCX 25 kb)
Fig. 2 Cultured leukemic cells maintain the stem cell capacity. a Representative FACS analysis of CD34 and CD38 expression profiles in primary
B-ALL cells from patient #1 in OP9 co-culture at indicated time points. b B-ALL cells from xenografts of patients #1, #4, and #7 were co-cultured
with OP9 stromal cells. After 6 weeks, cultured B-ALL cells were subjected to FACS analysis. Then CD34−CD38+ populations were enriched from
cultured B-ALL cells and were subsequently injected into groups of NSI mice for serial transplantations. Eight weeks after transplantation, BM cells
from xenografts were subjected for FACS analysis. Representative FACS analysis of gated CD45+ cells from xenografts or co-cultures
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Additional file 3: Table S3. Summary of mice engrafted with
different subpopulations of primary B-ALL cells from xenografts.
(DOCX 31 kb)
Additional file 4: Figure S1. Reconstitution of adult B-ALL in NSI mice.
(A) Left, spleens from of an NSI mouse engrafted with B-ALL cells and an
NSI mouse not injected with B-ALL cells. Right, weights of the spleens
from the mice engrafted with or without B-ALL (0.69 ± 0.24 versus 0.02 ±
0.02; p = 0.001). Data are shown as mean ± SEM. (B) Representative
FACS analysis of primary leukemic cells from patient #1, BM cells from
xenografts of patient #1 (mouse #140815N1), and BM cells from a
healthy donor. Red lines highlight the median values of hCD45 expression
levels in leukemic cells and in lymphoid cells. (C) Representative FACS
analysis of hCD10 and CD19 cells from patient #1 and leukemic cells from
xenograft of patient #1 (mouse #140815N1). (D) Representative FACS
analysis of hCD14 and hCD33 cells from BM cells from xenograft of
patient #1 (mouse #140815N1). (JPG 648 kb)
Additional file 5: Figure S2. Immunophenotypes of the leukemic cells
remain stable for serial transplantations. (A) Representative FACS analysis
of leukemic cells from patients #1, #3, and #7 and leukemic cells from
their xenografts after serial transplantations. (B) Representative of H&E
staining of blood smear (peripheral blood), spleen and bone marrow of
xenografts of patient #1 and patient #1 BM. Scale bars represent 100 μm
(JPG 1500 kb)
Additional file 6: Figure S3. Characterizations of CD34 and CD38
expression profiles in B-ALL cells in patients and xenografts. BM cells of
xenografts were analyzed by FACS to determine their expression profiles
of CD34 and CD38. (JPG 1305 kb)
Additional file 7: Figure S4. Reevaluation of purities of primary B-ALL
cells after sorting. (A) Representative FACS analysis of sorted CD34+CD38−,
CD34+CD38+, and CD34−CD38+ fractions from xenograft of patient #1. (B)
Representative FACS analysis of purified CD34+CD38+ and CD34−CD38+
fractions from xenograft of patient #3. (JPG 550 kb)
Additional file 8: Figure S5. Gene expression pattern in subpopulations
of B-ALL cells. (A, B) The immunophenotypes of patients #1 and #3
respected to CD34 and CD38 expression for RNA-Seq analysis. (C) The
expression levels of CD10, CD20, CD34, CD19, CD38, and CD33 in
indicated subpopulations from patients #1, #3, and two healthy donors.
(D) Hierarchical clustering shows different subpopulations of patient #1
and #3 are grouped together. (JPG 758 kb)
Additional file 9: Figure S6. The expression level of genes was
confirmed by qRT-PCR. (A) Relative expression levels of indicated genes
in patient #1 (blue) and patient #3 (red) cells were measured by qRT-PCR.
The results were normalized to β-ACTIN mRNA levels and represent the
means ± SEM. (n = 3). The qRT-PCR results were compared to the
expression levels of these genes in B-ALL cells from patient #1 and
patient #3 indicated by RNA-Seq analysis. (JPG 516 kb)
Additional file 10: Table S4. Characteristics of leukemic cells in co-
culture with OP9 stromal cells. (DOCX 18 kb)
Additional file 11: Table S5. Engrafted mice transplanted with cultured
leukemic cells. (DOCX 19 kb)
Additional file 12: Figure S7. Leukemic cells’ SNPs are conserved in ex
vivo. (A) Whole exome sequencing of the leukemia in xenografts (before
culture, B. C.), after culture (A. C.) and after transplantation (A. T.) revealed
the presence of genome mutations. Similar rates of nonsynonymous and
synonymous single nucleotide variants (SNVs) within the leukemia of
patient #1 and patient #7. (B, C) Venn diagram present B-ALL cells from
co-culture and B-ALL cells from xenografts share similar nonsynonymous
SNP profiles. (JPG 1513 kb)
Additional file 13: Figure S8. Single cell assays of primary adult B-ALL
cells. (A) Each NSI mouse was injected with a single primary B-ALL cell.
Sixteen weeks after transplantation, the BM compartments of hosts were
subjected to FACS analysis. (B) Representative FACS analysis of B-ALL cells
used for single cell transplantation (Before, left) and gated hCD45+ cells
from the BM compartments of the successfully grafted hosts (After, right).
(JPG 494 kb)
Additional file 14: Table S6. Summary of single B-ALL cell
xenotransplantation. (DOCX 27 kb)
Additional file 15: Table S7. Antibodies used for multicolor FACS
analysis and cell sorting. (DOCX 19 kb)
Additional file 16: Table S8. Primers used for qRT-PCR and PCR.
(DOCX 20 kb)
Additional file 17: Supplementary methods (Additional file 15: Table S7
and Additional file 16: Table S8). (DOCX 44 kb)
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